Evidence map›Paper›PMID 26070916›Full record

ArticleThe oncologist2015

Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers.

Walid L Shaib, Ludmila Katherine Martin, Minsing Choi, Zhengjia Chen, Kavya Krishna, Sungjin Kim, Edith Brutcher, Charles Staley, Shishir K Maithel, Philip Philip and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. PIPAC for Gastrointestinal Malignancies.Journal of clinical medicine · 2023
    Review
  10. Article
  11. Review
  12. ΔNp73 status in peritoneal and ovarian dissemination of appendicular adenocarcinoids (goblet cells).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Walid L ShaibDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Ludmila Katherine MartinDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Minsing ChoiDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Zhengjia ChenDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Kavya KrishnaDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Sungjin KimDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Edith BrutcherDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Charles StaleyDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Shishir K MaithelDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Philip PhilipDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Sherif Abdel-MisihDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Tanios S Bekaii-SaabDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
Bassel F El-RayesDepartment of Hematology and Oncology, Winship Cancer Institute, Division of Surgical Oncology, Winship Cancer Institute, and Department of Biostatistics, Emory University, Atlanta, Georgia, USA; Divisions of Hematology Oncology and Surgical Oncology, The Ohio State University, Columbus, Ohio, USA; Division of Hematology Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA bassel.el-rayes@emoryhealthcare.org.
Emory University · USThe Ohio State University · USThe Barbara Ann Karmanos Cancer Institute · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAppendiceal mucinous neoplasms (AMN) are a rare heterogeneous group of diseases. In the absence of randomized trials, AMN management is controversial. The goal of this study was to evaluate the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery on survival in AMN patients. PATIENTS AND

methodsPatient data including demographics, pathology, type of therapy, and outcomes were collected from Emory University, the Ohio State University, and Wayne State University databases. One of the three centers did not use HIPEC. Statistical analysis evaluating overall survival (OS) of AMN patients was performed.

resultsBetween 1990 and 2010, 163 AMN patients were identified. Histology showed 60 patients had diffuse peritoneal adenomucinosis, 88 had peritoneal mucinous carcinomatosis (PMCA), and 15 had PMCA with indeterminate or discordant features. Complete surgical resection was achieved in 76 patients. HIPEC was used in 79 patients. The median OS was 77 months for patients who received HIPEC compared with 25 months for patients who did not (p < .001). In multivariable analysis, histopathologic subtype (p < .001), complete surgical resection (p < .001), and HIPEC (p < .001) were independent predictors for improved OS. A survival advantage for AMN patients treated at HIPEC-treating centers was observed (p = .0026). After adjusting for HIPEC therapy, no significant survival difference was observed between the non-HIPEC-treating center and the HIPEC-treating centers (p = .094).

conclusionThe addition of HIPEC to cytoreductive surgery likely provides a survival advantage and should be considered in the treatment strategy for AMN.

Indexed as

Adenocarcinoma, MucinousAdultAgedAppendiceal NeoplasmsCytoreduction Surgical ProceduresFemaleFeverHumansInjections, IntraperitonealMaleMiddle AgedTertiary Care CentersTreatment OutcomeAppendiceal mucinous carcinomaHyperthermic intraperitoneal chemotherapySurvival

Identifiers

PMID26070916
PMCPMC4524750
OpenAlexW2162614038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.